About Us

Myrexis, Inc. is a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action. The Company has generated a strong pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis is focused on maximizing the therapeutic and commercial value of these molecules by developing potential first-in-class and/or best-in-class treatment options for patients with unmet needs.

Our lead product candidates in development include:

Our corporate strategy:

  • Develop first-in-class or best-in-class products
  • Move rapidly to proof of concept
  • Maximize value through selective partnering

To learn more about Myrexis, please contact us.